ArticleQuantitative imaging in medicine and surgery2025
Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nowadays, dynamic risk stratification (DRS) is the chosen strategy for monitoring papillary thyroid cancer (PTC). However, other variables contribute information to optimise monitoring. The objective of this study was to analyse the quantitative parameters of the single-photon emission computed tomography/computed tomography (SPECT/CT) imaging after treatment with post-surgical I-131 uptake, and to analyse those that predict a non-excellent response (NER) at 1 year of monitoring as well as their predictive capacity. Methods: A retrospective observational study was designed that included patients diagnosed with PTC and treatment with I-131. Monitoring was based on the DRS at 1 year comparing the patients that have an excellent response (ER) with those who have a response less than excellent (NER). For the study of the biokinetics of the I-131 in the post-surgical thyroid remnants, SPECT/CT images were acquired, as well as the following variables: the absorbed activity per the administered activity, percentage of remnant uptake at 2 and 7 days post-administration; and the accumulated activity over time. Results: Fifty-seven patients were studied and 103 remnants. Of them, 19.30% obtained NER. Among males, there was a higher percentage of NER, 45.45% while among females, 82.61% obtained ER (P=0.102). As for the surgical technique, the patients with ER, 78.26%, underwent total thyroidectomy (TT) with bilateral central lymph node dissection. Most of the patients who had TT, bilateral central and unilateral lateral lymph node dissection had NER (45.45% Conclusions: In PTC follow-up, the male gender, the absorbed dose, and the percentage of absorbed dose at 7 d should be considered along with the DRS, as tools to support future decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.